Clinical Trial Participant Injury Claims

1. Introduction

Clinical Trial Participant Injury Claims are legal claims made by a person who suffers physical injury, illness, disability, psychological harm, financial loss, or death as a consequence of participating in a clinical trial.

The central legal question is usually:

When a research participant is injured during a clinical trial, who is legally responsible for medical treatment and compensation, and what must the participant prove to obtain relief?

This area sits at the intersection of:

• medical negligence;
• pharmaceutical regulation;
• informed consent;
• consumer protection;
• constitutional rights;
• tort law;
• contract law;
• bioethics;
• research ethics;
• product liability;
• regulatory law; and
• compensation mechanisms for serious adverse events.

In India, the subject is particularly important because the New Drugs and Clinical Trials Rules, 2019 (NDCT Rules) establish a regulatory framework dealing with clinical-trial injuries and serious adverse events. The CDSCO's current clinical-trial framework specifically provides for compensation orders in applicable serious-adverse-event cases and requires payment within the prescribed period.

2. What Is a Clinical Trial Injury?

A clinical-trial injury may arise from:

1. the investigational drug;
2. a vaccine;
3. a medical device;
4. the trial procedure;
5. administration of placebo in circumstances covered by the applicable rules;
6. an adverse interaction;
7. inadequate medical monitoring;
8. negligent administration;
9. failure to respond to an adverse event;
10. inadequate informed consent;
11. protocol violations;
12. improper participant selection;
13. inadequate emergency treatment; or
14. other trial-related circumstances.

The injury may be:

• temporary;
• permanent;
• disabling;
• life-threatening;
• psychological;
• financial; or
• fatal.

3. Serious Adverse Event

Under the Indian regulatory framework, a Serious Adverse Event (SAE) is an untoward medical occurrence during a clinical trial that may result in:

• death;
• permanent disability;
• hospitalization;
• prolongation of hospitalization;
• significant disability or incapacity;
• congenital anomaly;
• birth defect; or
• a life-threatening event.

The distinction between an ordinary adverse event and a serious adverse event is important because serious events trigger specific regulatory reporting and compensation procedures.

4. Indian Legal Framework

A. New Drugs and Clinical Trials Rules, 2019

The NDCT Rules are central to modern Indian clinical-trial injury claims.

They provide a regulatory mechanism concerning:

• serious adverse events;
• medical management;
• causation;
• compensation;
• sponsor responsibility;
• investigator responsibility;
• Ethics Committee review;
• expert assessment; and
• regulatory oversight.

The CDSCO's SAE system expressly contemplates orders directing sponsors to pay compensation calculated under the applicable formula and requires information concerning payment and free medical management to be submitted to the regulator.

5. Medical Treatment and Compensation Are Distinct

One of the most important principles is that medical management and monetary compensation are not necessarily the same thing.

Where a trial-related adverse event occurs, the participant may be entitled to necessary medical management under the applicable regulatory framework.

A separate question is whether the participant is entitled to financial compensation.

Therefore:

Treatment obligation ≠ compensation obligation

A sponsor may have to provide medical treatment while the question of monetary compensation depends upon whether the regulatory requirements for trial-related injury are satisfied.

6. Causation Is Central

The most important issue in many participant-injury claims is:

Was the injury caused by participation in the clinical trial?

The mere fact that:

Trial → participant experienced illness

does not automatically establish:

Trial → legally compensable injury caused by trial intervention.

This distinction was directly examined by the Madras High Court in Asif Riaz v. Government of India (2024).

The Court found that although the participant experienced a serious medical condition following administration of a trial vaccine, the expert assessment concluded that the condition was not attributable to the vaccine. The Court therefore declined compensation.

This is an important illustration of the difference between temporal association and legal causation.

7. Important Case Laws

1. Swasthya Adhikar Manch, Indore v. Union of India

Supreme Court of India

This is one of the most important Indian cases concerning clinical-trial regulation.

The litigation challenged deficiencies in the regulatory system governing clinical trials, including:

• informed consent;
• safety;
• monitoring;
• compensation;
• regulatory approval; and
• protection of trial participants.

In one stage of the proceedings, the Supreme Court recorded information concerning hundreds of participants who had experienced serious adverse effects and noted concerns about whether compensation had been provided.

The litigation subsequently contributed to the development and strengthening of the regulatory framework, including the eventual NDCT Rules, 2019. The Supreme Court proceedings continued to monitor the regulatory framework; in 2024 the Court was informed that the 2019 Rules had been enacted.

Legal significance

The case establishes the broader principle that:

Clinical research involving human subjects is subject to significant public-law and regulatory scrutiny because participants require protection against exploitation and unsafe research practices.

Importance for injury claims

It reinforces the importance of:

• informed consent;
• risk-benefit assessment;
• compensation mechanisms;
• Ethics Committees;
• regulatory supervision;
• participant protection.

8. Asif Riaz v. Government of India (Madras High Court, 2024)

This is one of the most directly relevant Indian authorities.

Facts

The petitioner voluntarily participated in a COVID-19 vaccine clinical trial.

After receiving the trial vaccine, he developed serious neurological complications and sought substantial compensation.

He argued that the complications were caused by the vaccine.

The respondents relied upon medical evaluation and an expert committee, which concluded that the adverse event was not attributable to the vaccine.

Decision

The Court accepted that the petitioner had suffered a serious medical condition.

However, it distinguished:

a serious adverse event

from

a serious adverse event caused by the clinical-trial intervention.

The Court held that compensation under the applicable regulatory framework required the necessary causal connection to be established.

Principle

Causation is essential for regulatory compensation.

The Court explained that where the serious adverse event is established to be directly relatable to the trial vaccine, the sponsor would have the corresponding obligation to provide compensation and necessary treatment; where the event is found unrelated, compensation cannot automatically be imposed merely because the participant was in the trial.

Significance

This case is particularly important for exam purposes because it demonstrates:

• the importance of expert medical evidence;
• the role of the SAE assessment mechanism;
• the distinction between temporal sequence and causation;
• the relevance of informed consent;
• the statutory/regulatory compensation framework.

9. Sanjay Gupta & Ors. v. State of Uttar Pradesh & Ors. (2022)

This case was relied upon before the Madras High Court in Asif Riaz in connection with clinical-trial injury issues.

Its significance lies in the broader judicial approach toward participant protection and the regulatory consequences of adverse events.

In Asif Riaz, the petitioner attempted to rely upon Sanjay Gupta to support the proposition that the adverse medical condition should attract compensation, but the Madras High Court ultimately distinguished the circumstances because the expert determination in Asif Riaz did not establish a causal connection between the vaccine and the injury.

Legal lesson

A claimant cannot rely merely upon the existence of another clinical-trial injury case.

The claimant must establish the specific factual and causal basis for his or her own injury.

10. Samira Kohli v. Dr. Prabha Manchanda (2008)

Supreme Court of India

Although not a clinical-trial case, this is a leading Indian authority on informed consent, which is highly relevant to participant-injury claims.

The Supreme Court emphasized that medical treatment requires meaningful consent and that consent for one procedure does not automatically amount to consent for every materially different procedure.

Clinical-trial relevance

Clinical-trial participants are generally required to understand:

• the investigational nature of the intervention;
• known and reasonably foreseeable risks;
• alternatives;
• procedures involved;
• possible benefits;
• compensation arrangements;
• treatment available in case of injury;
• the voluntary nature of participation.

Principle

Informed consent is not merely a signature on a document.

A participant must be given adequate information to make an informed decision.

11. Jacob Mathew v. State of Punjab (2005)

Supreme Court of India

This is a leading Indian medical-negligence case.

The Supreme Court discussed the standard of professional medical care and distinguished negligence from a mere error of judgment.

Clinical-trial relevance

Suppose a participant suffers an injury because:

• the investigator administered the drug negligently;
• emergency treatment was delayed;
• the trial protocol was ignored;
• monitoring was inadequate; or
• an obvious adverse reaction was negligently disregarded.

In such circumstances, a conventional medical negligence claim may arise independently of the regulatory compensation mechanism.

Principle

Not every unsuccessful medical outcome constitutes negligence.

The claimant generally needs to establish the required elements of professional negligence.

12. Indian Medical Association v. V.P. Shantha (1995)

Supreme Court of India

This landmark decision established important principles concerning the application of consumer-protection law to medical services.

Clinical-trial relevance

Where a participant's relationship with an institution or medical provider falls within applicable consumer-law principles, questions may arise concerning:

• deficient medical service;
• negligent treatment;
• failure to provide promised services;
• improper medical management.

However, clinical research and medical treatment are not necessarily legally identical, so the exact applicability of consumer law must be assessed from the facts and governing legislation.

Principle

A participant may have remedies under multiple legal regimes depending upon the nature of the relationship and the conduct involved.

13. Spring Meadows Hospital v. Harjol Ahluwalia (1998)

Supreme Court of India

The Supreme Court recognized the availability of compensation for medical negligence and emphasized the importance of protecting patients from deficient medical treatment.

Clinical-trial relevance

If a clinical-trial participant suffers injury because of:

• negligent administration;
• failure to monitor;
• inadequate emergency care;
• improper medical management;

a claim may potentially be framed as medical negligence.

Importance

It reinforces the distinction between:

injury caused by the investigational intervention

and

injury caused by negligent medical conduct.

Both may produce liability, but through different legal pathways.

14. Montgomery v. Lanarkshire Health Board (2015)

Supreme Court of the United Kingdom

This is a leading modern informed-consent case.

The UK Supreme Court emphasized patient autonomy and held that doctors must take reasonable care to ensure that patients are aware of material risks and reasonable alternatives.

Clinical-trial relevance

The case is particularly useful for understanding the ethical and legal foundation of informed consent.

A participant's agreement to participate cannot be treated as a blanket waiver of every possible legal right.

Principle

Autonomous decision-making requires adequate disclosure of material risks.

This is especially important where the participant is a healthy volunteer exposed to an investigational intervention for research purposes.

15. Chester v. Afshar (2004)

House of Lords, United Kingdom

This case dealt with failure to provide adequate information concerning a medical procedure and the relationship between failure to warn and subsequent injury.

Clinical-trial relevance

It demonstrates the importance of the duty to disclose material risks.

In clinical trials, informed consent is especially important because the participant may not receive an established therapeutic benefit and may instead accept risks for the purpose of generating scientific knowledge.

16. Dressen v. AstraZeneca AB (Tenth Circuit, 2026)

This is a particularly important recent authority.

Facts

The plaintiff participated in AstraZeneca's experimental COVID-19 vaccine clinical trial.

The informed-consent documentation stated that AstraZeneca would provide certain medical treatment or referrals if the participant became ill or injured and contained provisions concerning compensation/insurance.

After suffering serious medical problems, she sought care and compensation.

She brought a claim against AstraZeneca.

2026 decision

The Tenth Circuit held that the PREP Act's immunity provisions could extend broadly to claims for loss, including breach-of-contract damages, but remanded for consideration of whether AstraZeneca had waived immunity through the informed-consent form.

Importance

This is a highly significant development because it demonstrates that the informed-consent document itself can become legally important beyond ordinary medical consent.

It may contain:

• promises concerning treatment;
• compensation provisions;
• insurance arrangements;
• participant rights;
• dispute-resolution provisions.

Principle

A clinical-trial participant's claim may potentially involve contractual obligations arising from representations in the consent documentation, although statutory immunity can significantly affect the available remedies.

17. The Seven Key Cases at a Glance

Additional relevant medical-negligence authorities include Indian Medical Association v. V.P. Shantha and Spring Meadows Hospital v. Harjol Ahluwalia.

18. Who May Be Liable?

Potential defendants may include:

1. Sponsor

The pharmaceutical, biotechnology or medical-device company financing or sponsoring the trial.

2. Principal Investigator

The doctor or researcher responsible for conducting the trial.

3. Clinical Research Organisation

A CRO managing trial activities on behalf of the sponsor.

4. Hospital or research institution

The institution where the trial is conducted.

5. Manufacturer

Particularly where a defective product or manufacturing problem is involved.

6. Ethics Committee

Usually subject to a different and more limited legal analysis; liability depends upon its statutory role, conduct and applicable law.

7. Government/regulator

Potentially where there is a legally actionable failure to perform a statutory duty, although governmental liability raises additional public-law and sovereign-immunity issues.

19. Sponsor Liability

The sponsor is often the central party in clinical-trial compensation arrangements.

The sponsor may have obligations concerning:

• medical management;
• adverse-event reporting;
• compensation;
• insurance;
• monitoring;
• regulatory compliance;
• informed consent;
• trial protocol;
• record keeping.

Indian regulatory materials expressly contemplate compensation orders directed against sponsors in applicable SAE cases.

20. Investigator Liability

The investigator may incur liability where the injury results from:

• negligence;
• protocol violation;
• inadequate monitoring;
• improper administration;
• failure to report;
• failure to obtain valid consent;
• failure to provide emergency care;
• falsification of trial records.

Importantly, the mere occurrence of an adverse event does not automatically prove investigator negligence.

21. Role of Informed Consent

Informed consent has two distinct functions.

First function — ethical

It protects participant autonomy.

Second function — legal

It provides evidence concerning:

• information supplied;
• risks disclosed;
• alternatives;
• compensation arrangements;
• participant rights;
• treatment arrangements.

But:

Informed consent is not necessarily a waiver of negligence or statutory rights.

A participant agreeing to known risks does not necessarily consent to:

• negligent conduct;
• fraud;
• protocol violations;
• failure to provide required medical treatment;
• deliberate misconduct.

22. Can a Participant Say "I Consented, But I Still Want Compensation"?

Yes, potentially.

Consent to participate in a trial generally means:

"I understand the disclosed risks and voluntarily agree to participate."

It does not necessarily mean:

"I permanently waive every right to compensation for legally compensable injury."

The exact effect depends upon:

• applicable statute;
• consent document;
• jurisdiction;
• type of claim;
• nature of injury;
• contractual terms;
• regulatory rules.

The Dressen litigation illustrates the importance of carefully examining the actual informed-consent document and the interaction between contractual promises and statutory immunity.

23. Causation in Clinical-Trial Injury Claims

Causation can be divided into several questions.

A. Temporal relationship

Did the injury occur after the intervention?

This is relevant but insufficient by itself.

B. Biological plausibility

Is there a scientifically plausible connection?

C. Alternative causes

Could the injury have resulted from:

• pre-existing disease;
• another medicine;
• infection;
• unrelated medical condition;
• placebo;
• environmental factor?

D. Expert determination

What do qualified medical experts conclude?

E. Regulatory determination

Has the relevant regulatory authority or expert committee determined whether the event is trial-related?

24. "Adverse Event" Is Not Automatically "Compensable Injury"

This distinction is extremely important.

Example

A participant receives an experimental medicine.

Two days later:

develops appendicitis.

The event may be serious.

But if medical evidence establishes that the appendicitis was unrelated to the investigational product or trial procedure, compensation under a trial-injury regime may not follow.

This is essentially the issue considered in Asif Riaz. The participant experienced genuine serious medical complications, but the Court concluded that the necessary causal connection to the trial vaccine was not established.

25. Injury From Placebo

A participant receiving a placebo is not necessarily outside the protection of the clinical-trial compensation framework.

Indian regulatory guidance has recognized that serious adverse events associated with placebo administration can raise compensation questions where the applicable conditions are satisfied.

This reflects an important principle:

Research participation itself can create legally relevant risks even where the participant does not receive the investigational drug.

26. Death of a Clinical-Trial Participant

Where a participant dies, the legal framework can involve:

• compensation to nominee/legal heirs;
• medical expenses;
• loss of dependency;
• funeral expenses;
• investigation of the SAE;
• causation;
• insurance;
• regulatory proceedings;
• civil claims;
• negligence claims.

Indian clinical-trial regulations specifically contemplate compensation to legal heirs/nominees in appropriate death cases.

Government information has historically recorded compensation paid in clinical-trial-related deaths, demonstrating that compensation mechanisms have been operationalized in India.

27. Permanent Disability

Permanent disability can produce significantly larger consequences.

Potential heads of loss may include:

• medical expenses;
• rehabilitation;
• future treatment;
• loss of earning capacity;
• loss of future income;
• disability;
• pain and suffering;
• attendant expenses;
• psychological harm;
• reduced quality of life.

The applicable statutory compensation formula may operate separately from a traditional tort calculation.

28. Temporary Injury

Temporary injuries may also attract legal consequences where the applicable regulatory requirements are satisfied.

Possible losses include:

• hospitalization;
• medication;
• lost income;
• travel;
• rehabilitation;
• temporary incapacity.

29. Psychological Injury

Clinical-trial participation may also produce:

• psychological trauma;
• anxiety;
• depression;
• PTSD-type symptoms;
• loss of normal functioning.

Whether psychological injury qualifies for compensation depends upon:

• applicable law;
• medical evidence;
• causal connection;
• regulatory framework;
• contractual terms.

30. Regulatory Compensation Versus Civil Damages

This distinction is essential.

Regulatory compensation

Usually arises from:

• NDCT Rules;
• serious adverse event procedures;
• prescribed formulas;
• regulatory determinations.

Civil damages

May arise from:

• negligence;
• breach of contract;
• product liability;
• consumer law;
• tort;
• other statutory causes of action.

Therefore:

Receiving regulatory compensation does not necessarily mean that every possible civil claim disappears.

Conversely, satisfying a regulatory compensation mechanism does not automatically establish medical negligence.

31. Clinical Trial Injury and Medical Negligence

A participant could potentially have two different theories.

Theory 1 — Trial-related injury

The investigational product or trial procedure caused the injury.

Theory 2 — Negligent treatment

The injury was worsened or caused by negligent conduct of the medical team.

Example

A participant suffers an adverse reaction to an investigational drug.

The reaction itself may fall within the clinical-trial compensation framework.

But if the investigator:

• ignores the reaction;
• fails to provide emergency treatment;
• delays hospitalization;

and the delay causes permanent disability, a separate negligence claim may arise.

32. Clinical Trial Injury and Product Liability

A participant may potentially argue that a drug/device was defective.

Potential categories include:

• manufacturing defect;
• design defect;
• inadequate warnings;
• inadequate instructions.

However, clinical-trial products are subject to specialized regulatory regimes, and statutory immunities or special protections may apply in particular jurisdictions.

Therefore, ordinary product-liability principles cannot simply be assumed to apply without examining the governing legislation.

33. Clinical Trial Injury and Consumer Protection

Consumer-law remedies may become relevant where the relationship falls within the applicable definition of consumer/service.

Indian Medical Association v. V.P. Shantha provides the foundational jurisprudence concerning medical services and consumer law.

However, clinical research has distinctive characteristics:

• participants may volunteer rather than purchase treatment;
• the primary purpose is research;
• experimental interventions may lack established therapeutic value.

Consequently, consumer-law applicability should be analyzed carefully rather than assumed.

34. Evidence Required in a Participant Injury Claim

A strong claim should normally preserve:

Medical records

• admission records;
• discharge summaries;
• diagnostic reports;
• prescriptions;
• treatment records.

Trial records

• participant information sheet;
• informed-consent form;
• trial identification;
• dosage information;
• trial visits;
• protocol documents where available.

Regulatory records

• SAE reports;
• Ethics Committee findings;
• expert committee reports;
• regulator decisions.

Financial evidence

• medical bills;
• rehabilitation expenses;
• lost wages;
• future treatment estimates.

Causation evidence

• medical opinions;
• scientific literature;
• temporal sequence;
• differential diagnosis;
• expert evidence.

35. Importance of the Informed-Consent Form

The informed-consent document should be examined for:

• identity of sponsor;
• identity of investigator;
• risks;
• expected benefits;
• alternatives;
• compensation arrangements;
• insurance;
• medical treatment;
• confidentiality;
• withdrawal rights;
• contact information;
• dispute-resolution provisions.

The Dressen case demonstrates how an informed-consent form can become central to litigation over compensation and contractual obligations.

36. Regulatory Reporting

Clinical-trial systems require serious adverse events to be reported promptly.

Indian regulatory materials state that serious adverse events are subject to prescribed reporting and compensation procedures. Earlier amendments specifically required investigators to report SAEs to the regulator, Ethics Committee and sponsor within prescribed timelines.

Failure to properly report an SAE may itself create:

• regulatory liability;
• disciplinary consequences;
• evidentiary problems;
• possible negligence arguments.

37. Ethics Committee's Role

The Ethics Committee is intended to protect participant:

• safety;
• rights;
• welfare;
• informed consent.

It may examine:

• trial protocol;
• risk-benefit ratio;
• adverse events;
• consent procedures;
• compensation;
• continuing safety.

However, the precise legal liability of an Ethics Committee depends upon its institutional and statutory status.

38. Insurance

Clinical-trial insurance can play a significant role.

Insurance may cover:

• trial-related injury;
• death;
• medical treatment;
• compensation;
• investigator liability;
• sponsor liability.

But:

Insurance coverage does not itself establish causation.

The claimant still may need to demonstrate that the injury falls within the insured and legally compensable category.

39. No-Fault Compensation Versus Fault-Based Liability

This is an important theoretical distinction.

No-fault system

The participant receives compensation when specified conditions are met without proving negligence.

Advantages:

• faster;
• simpler;
• participant-friendly;
• avoids difficult negligence litigation.

Fault-based system

The participant must prove:

1. duty;
2. breach;
3. causation;
4. damage.

Clinical-trial compensation systems may incorporate elements of both approaches depending upon jurisdiction and the particular statutory mechanism.

India's regulatory compensation framework is particularly significant because it can provide a mechanism for trial-related injury without requiring the participant to establish conventional medical negligence in every case.

40. United States Position

The United States historically has not adopted a comprehensive national no-fault compensation system for all research-related injuries.

Instead, injured participants may have to rely on:

• state tort law;
• contract;
• institutional policies;
• insurance;
• federal compensation programs in particular contexts;
• informed-consent documentation.

Current US research rules require information concerning whether compensation or medical treatment is available for research-related injury in specified higher-risk studies, but federal regulations generally do not themselves establish a universal compensation entitlement.

This makes the Dressen litigation particularly interesting.

41. United Kingdom Position

The UK has developed contractual/indemnity mechanisms for certain clinical research settings.

For Phase I studies, guidance can provide for compensation where injury is causally connected to participation, including compensation without requiring proof of fault in specified circumstances.

This demonstrates an important comparative distinction:

Some systems emphasize no-fault or contractual compensation, while others rely more heavily on ordinary civil litigation.

42. Key Defences

Sponsors and investigators may defend claims by arguing:

1. No causal connection

The injury was unrelated to the trial.

2. Alternative cause

The condition resulted from another disease or circumstance.

3. Proper informed consent

The participant was adequately informed of known risks.

4. Proper protocol compliance

The trial was conducted according to the approved protocol.

5. Appropriate medical care

The participant received proper treatment.

6. Expert evidence

Independent experts concluded that the intervention did not cause the injury.

7. Statutory immunity

Particular products or circumstances may attract legislative immunity.

The Dressen case demonstrates how statutory immunity can become a major issue in participant-injury litigation.

43. Limitations of Informed Consent as a Defence

A sponsor cannot necessarily argue:

"The participant signed the consent form, therefore there can be no liability."

Consent may protect against claims based upon undisputed inherent risks that were properly disclosed, but it does not necessarily excuse:

• negligence;
• fraud;
• concealment;
• protocol violations;
• failure to provide mandatory treatment;
• statutory breaches;
• misleading information.

The principle of informed consent is therefore fundamentally about autonomy and disclosure, not unrestricted contractual immunity.

44. Important Legal Distinctions

45. A Hypothetical Example

Suppose a participant joins a Phase III drug trial.

After receiving the investigational drug:

• severe neurological symptoms develop;
• the participant is hospitalized;
• permanent disability follows.

The legal analysis should proceed in stages.

Stage 1 — Was it an SAE?

Yes, if it satisfies the statutory definition.

Stage 2 — Was it trial-related?

Medical and expert evidence must address causation.

Stage 3 — Was proper treatment provided?

If not, an additional negligence issue may arise.

Stage 4 — Was informed consent valid?

Was the material risk disclosed?

Stage 5 — What does the compensation framework provide?

The NDCT Rules and applicable regulatory orders must be examined.

Stage 6 — Is additional civil liability possible?

Potentially, depending upon negligence, contract, product liability or another legal basis.

46. Claim Process in India

A participant or legal heir may generally need to proceed through several channels.

Step 1 — Preserve medical evidence

Collect all treatment records.

Step 2 — Notify the investigator/sponsor

The injury should be formally documented.

Step 3 — SAE reporting

Ensure that the event is properly reported through the clinical-trial regulatory mechanism.

Step 4 — Ethics Committee

The Ethics Committee may review the event.

Step 5 — Expert assessment

Causation may be evaluated by the competent expert mechanism.

Step 6 — Regulatory determination

The regulator may determine applicable compensation.

Step 7 — Compensation

The sponsor may be directed to pay the prescribed amount.

Step 8 — Additional legal remedies

Where appropriate, the participant may separately consider:

• civil proceedings;
• consumer proceedings;
• writ proceedings;
• medical-negligence proceedings;
• contractual remedies.

The appropriate route depends upon the facts and applicable law.

47. Compensation Calculation

In India, the regulatory framework provides a prescribed methodology for calculating compensation for certain trial-related injuries/deaths.

The calculation can consider factors such as:

• age;
• risk;
• seriousness;
• disability;
• death;
• income-related considerations;
• relevant statutory parameters.

The CDSCO specifically states that compensation orders in applicable SAE cases use the formula prescribed in the Seventh Schedule of the NDCT Rules, 2019.

Thus, clinical-trial compensation is not necessarily calculated in exactly the same manner as ordinary tort damages.

48. Future Losses

Where an injury causes permanent disability, a participant may potentially suffer:

• reduced earning capacity;
• continuing medical costs;
• rehabilitation expenses;
• dependency consequences;
• loss of quality of life.

The treatment of these losses depends upon the applicable compensation mechanism and whether the participant pursues separate civil remedies.

49. Clinical Trial Participant Injury and Constitutional Law

In India, serious clinical-trial injury can potentially engage constitutional principles.

Article 21

Protection of life and bodily integrity.

Article 14

Non-arbitrariness and equal protection.

Article 19

Potentially relevant in appropriate contexts concerning autonomy and information.

Public-law accountability

Government regulatory decisions may be subject to judicial review where a public-law duty is implicated.

However, constitutional remedies are not a substitute for every private compensation claim.

50. Core Legal Issues in Examination or Litigation

A clinical-trial participant injury problem should generally be analyzed through these questions:

1. Was the person a validly enrolled participant?

2. Was informed consent properly obtained?

3. Was the trial legally authorized?

4. Was the intervention administered according to protocol?

5. Did a serious adverse event occur?

6. Was the event causally related to the trial?

7. Was appropriate medical treatment provided?

8. Was the SAE properly reported?

9. Is regulatory compensation available?

10. Is there independent negligence?

11. Is there contractual liability?

12. Is product liability implicated?

13. Does statutory immunity apply?

14. What remedy is appropriate?

51. Comparative Case-Law Matrix

52. Most Important Legal Principles

Principle 1 — Participation does not eliminate legal protection

A participant voluntarily entering a clinical trial does not automatically surrender legal rights.

Principle 2 — Consent does not equal waiver of negligence

A participant may accept disclosed risks without consenting to negligent conduct.

Principle 3 — Causation is critical

A medical problem occurring during or after a trial is not automatically a trial-related injury.

Principle 4 — Medical treatment and compensation are distinct

A sponsor may have medical-management obligations even where monetary compensation is disputed.

Principle 5 — Regulatory compensation differs from civil damages

The two mechanisms may have different standards, procedures and remedies.

Principle 6 — Scientific evidence is central

Expert medical evidence often determines whether an adverse event is attributable to the investigational product.

Principle 7 — Informed consent must be meaningful

A signature alone does not necessarily establish valid informed consent.

Principle 8 — Trial documents can have contractual significance

As Dressen demonstrates, promises contained in consent documents can become relevant to litigation.

53. Conclusion

Clinical Trial Participant Injury Claims protect individuals who undertake risks for medical research and scientific advancement.

The Indian framework has evolved considerably. The litigation in Swasthya Adhikar Manch v. Union of India exposed significant concerns regarding clinical-trial safety, informed consent and compensation and contributed to the development of a stronger regulatory framework.

The most important modern Indian authority for the causation issue is Asif Riaz v. Government of India, where the Madras High Court emphasized that a serious medical event following administration of a trial vaccine does not by itself establish entitlement to compensation; the required causal connection must be established.

At the same time, ordinary medical-law principles remain important. Samira Kohli, Jacob Mathew, V.P. Shantha and Spring Meadows Hospital help explain consent, negligence and medical-service liability. Comparative authorities such as Montgomery, Chester, and the recent Dressen v. AstraZeneca demonstrate how participant autonomy, contractual promises and statutory immunity can interact.

The fundamental legal proposition can therefore be stated as:

A clinical-trial participant does not assume all risks merely by volunteering for research. Where a trial-related injury is established, the participant may have regulatory, contractual, tortious, consumer or constitutional remedies depending upon the applicable legal framework; however, compensation ordinarily requires a legally sufficient connection between the injury and the trial, and informed consent does not automatically extinguish liability for negligence, statutory violations or other actionable misconduct.

India's present system therefore seeks to balance two competing objectives: encouraging legitimate medical research while ensuring that the human subjects who bear the risks of that research are adequately protected, medically cared for and compensated where the law establishes entitlement.